Abstract：
MicroRNAs (miRNAs) have emerged as crucial regulators of gene expression, playing pivotal roles in various biological processes, including cancer development and progression. Among them, miR-125b has garnered significant attention due to its multifaceted functional roles in human hepatocellular carcinoma (HCC). Extensive research has revealed that miR-125b plays a dual role in HCC, acting as both a tumor suppressor and an oncogene depending on the context. As a tumor suppressor, miR-125b exerts its inhibitory effects on HCC by targeting key oncogenic pathways and genes involved in cell proliferation, migration, invasion, and angiogenesis. Its downregulation in HCC is frequently observed and correlates with aggressive tumor characteristics and poor prognosis. Conversely, miR-125b can also function as an oncogene in specific HCC subtypes or under certain conditions. It has been shown to promote HCC growth, metastasis, and therapeutic resistance by targeting tumor suppressor genes, modulating the epithelial-mesenchymal transition (EMT) process, and enhancing cancer stem cell-like properties. The upregulation of miR-125b in HCC has been associated with advanced disease stages and unfavorable clinical outcomes. Furthermore, the dysregulation of miR-125b expression in HCC is influenced by a complex network of regulatory mechanisms. Understanding these regulatory mechanisms is crucial for deciphering the precise functional roles of miR-125b in HCC and exploring its potential as a diagnostic biomarker or therapeutic target. In the current review study, we comprehensively elucidated the diverse functional roles of miR-125b in HCC, providing a comprehensive overview of its regulatory mechanisms and impact on key cellular processes involved in HCC progression.
摘要：
MicroRNAs（miRNAs）已经成为基因表达的关键调节因子，在各种生物过程中发挥关键作用，包括癌症的发展和进展。其中,miR-125b由于其在人类肝细胞癌（HCC）中的多方面功能作用而引起了广泛关注。广泛的研究表明，miR-125b在肝癌中起着双重作用，根据具体情况，既是肿瘤抑制因子又是癌基因。作为肿瘤抑制剂，miR-125b通过靶向关键致癌通路和参与细胞增殖的基因发挥其对肝癌的抑制作用，迁移,入侵,和血管生成。经常观察到其在HCC中的下调，并与侵袭性肿瘤特征和不良预后相关。相反，miR-125b还可以在特定HCC亚型中或在某些条件下充当癌基因。它已被证明可以促进肝癌的生长，转移,和通过靶向肿瘤抑制基因的治疗抗性，调节上皮-间质转化（EMT）过程，并增强癌症干细胞样特性。miR-125b在HCC中的上调与晚期疾病阶段和不利的临床结果相关。此外，miR-125b在HCC中的表达失调受到复杂调节机制网络的影响.了解这些调控机制对于破译miR-125b在HCC中的精确功能作用以及探索其作为诊断生物标志物或治疗靶标的潜力至关重要。在当前的综述研究中，我们全面阐明了miR-125b在肝癌中的不同功能作用，全面概述了其调控机制以及对HCC进展中涉及的关键细胞过程的影响。
